Vaccines and monoclonal antibodies: new tools for malaria control
Clinical Microbiology Reviews · 2024
DOI: 10.1128/cmr.00071-23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, 2024. Verfasst von Kazutoyo Miura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland,…. Hauptthemen laut MEDLINE: Malaria Vaccines, Antibodies, Monoclonal. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bloomberg Philanthropies (BP), PATH-MVI, Intramural program NIAID/NIH.
Abstract (Originalsprache)
Malaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to develop new tools, such as vaccines and monoclonal antibodies (mAbs), to fight malaria. In the last 2 years, the first and second malaria vaccines, both targeting Plasmodium falciparum circumsporozoite proteins (PfCSP), have been recommended by the World Health Organization to prevent P. falciparum malaria in children living in moderate to high transmission areas. While the approval of the two malaria vaccines is a considerable milestone in vaccine development, they have much room for improvement in efficacy and durability. In addition to the two approved vaccines, recent clinical trials with mAbs against PfCSP, blood-stage vaccines against P. falciparum or P. vivax , and transmission-blocking vaccine or mAb against P. falciparum have shown promising results. This review summarizes the development of the anti-PfCSP vaccines and mAbs, and recent topics in the blood- and transmission-blocking-stage vaccine candidates and mAbs. We further discuss issues of the current vaccines and the directions for the development of next-generation vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Malaria Research Institute, Baltimore, Maryland, USA.
ORCID-Profile: Kazutoyo Miura, Fidel Zavala
Förderung
- Bloomberg Philanthropies (BP)
- PATH-MVI
- Intramural program NIAID/NIH
- Bill and Melinda Gates Foundation
Zitieren
APA
Miura, K., Flores-Garcia, Y., Long, C. A., & Zavala, F. (2024). Vaccines and monoclonal antibodies: new tools for malaria control. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00071-23
Vancouver
Miura K, Flores-Garcia Y, Long CA, Zavala F. Vaccines and monoclonal antibodies: new tools for malaria control. Clinical Microbiology Reviews. 2024. doi:10.1128/cmr.00071-23
BibTeX
@article{Miura2024,
author = {Miura, Kazutoyo and Flores-Garcia, Yevel and Long, Carole A and Zavala, Fidel},
title = {Vaccines and monoclonal antibodies: new tools for malaria control},
journal = {Clinical Microbiology Reviews},
year = {2024},
doi = {10.1128/cmr.00071-23}
}
EUVIMED